The Role of Theranostics in Modern Oncology Practice
- Jul 14
- 3 min read
Updated: Aug 5
Precision Oncology Is Changing Clinical Care
Cancer treatment is increasingly moving beyond tumour location and histology alone. Advances in molecular imaging, biomarker identification and targeted radionuclide therapies are enabling more personalised treatment approaches that can better characterise disease and inform therapeutic decision-making.
Theranostics sits at the centre of this evolution. By combining diagnostic imaging with targeted therapy using related molecular compounds, theranostics supports a more individualised approach to patient care. This integrated model enables clinicians to identify suitable patients, visualise disease, monitor treatment response and deliver therapy using the same biological target.
As evidence continues to grow and new therapeutic options emerge, theranostics is becoming an increasingly important component of multidisciplinary oncology practice across Australia and internationally.
What Is Driving Adoption?
Several factors are contributing to the expanding role of theranostics within modern oncology:
Greater understanding of tumour biology and molecular targets
Advances in PET imaging and radiopharmaceutical development
Increasing availability of targeted radionuclide therapies
Growing clinical evidence supporting personalised treatment pathways
Stronger collaboration between oncology, nuclear medicine and research communities
Collectively, these developments are helping shift cancer care towards more precise, patient-centred treatment strategies.
Current Clinical Applications
Theranostics has established clinical applications in several cancer types, with ongoing research continuing to broaden its potential.
Prostate Cancer
Prostate-specific membrane antigen (PSMA)-targeted imaging and therapy have transformed the management of advanced prostate cancer. Molecular imaging can assist in disease detection, staging and treatment planning, while targeted radionuclide therapies provide additional treatment options for appropriately selected patients.
Neuroendocrine Tumours
Somatostatin receptor imaging and peptide receptor radionuclide therapy (PRRT) have become established components of care for many patients with advanced neuroendocrine tumours. These approaches allow clinicians to assess receptor expression before considering targeted treatment.
Emerging Applications
Clinical research continues to investigate theranostic approaches across additional tumour types, including:
Breast cancer
Lung cancer
Brain tumours
Pancreatic cancer
Ovarian cancer
Other solid tumours expressing suitable molecular targets
Many of these applications remain under active investigation through clinical trials and translational research programs.
The Importance of Multidisciplinary Collaboration
Successful theranostics programs rely on coordinated multidisciplinary care.
Optimal patient management often involves collaboration between:
Medical oncologists
Radiation oncologists
Nuclear medicine physicians
Radiologists
Surgeons
Medical physicists
Radiopharmacists
Specialist nurses
Researchers and clinical trial teams
Allied health professionals
Each discipline contributes unique expertise throughout the patient journey—from diagnosis and staging through treatment planning, therapy delivery, follow-up imaging and long-term care.
Multidisciplinary tumour board discussions are increasingly important when considering patients who may benefit from theranostic approaches.
Research, Innovation and Clinical Trials
Rapid innovation continues to expand the theranostics landscape.
Researchers worldwide are investigating:
Novel radionuclides
New targeting molecules
Combination therapies
Earlier treatment settings
Expanded disease indications
Improved imaging technologies
Patient selection biomarkers
Australia continues to play an active role in many areas of radiopharmaceutical research and clinical development through collaboration between hospitals, universities, research institutes and industry.
Clinical trials remain essential for generating high-quality evidence that informs future standards of care and improves patient outcomes.
Challenges to Wider Implementation
Despite significant progress, several factors continue to influence broader adoption of theranostics.
Awareness and Education
Awareness of theranostic pathways varies across healthcare settings. Continued education is important to ensure clinicians understand evolving indications, referral pathways and emerging evidence.
Access and Equity
Patient access can differ depending on geographic location, availability of specialised centres and local referral pathways. Addressing these variations remains an important consideration for healthcare systems.
Infrastructure and Workforce
Delivering theranostic services requires specialised infrastructure, trained multidisciplinary teams, radiopharmaceutical production capability and coordinated clinical workflows. Continued investment in workforce development and service capacity will support future growth.
Evidence Generation
As new therapies emerge, ongoing clinical research will remain critical to refining patient selection, optimising treatment sequencing and supporting future reimbursement and policy decisions.
Looking Ahead
Theranostics represents more than a new treatment modality—it reflects an evolving model of precision oncology that integrates diagnostics, therapy and multidisciplinary collaboration around the individual patient.
As research progresses and clinical experience grows, theranostics is expected to continue expanding across multiple tumour types and healthcare settings. Achieving this potential will require sustained collaboration between clinicians, researchers, healthcare organisations, policymakers, industry and patient advocates.
By supporting education, research, collaboration and evidence-informed discussion, the healthcare community can help ensure that more patients have the opportunity to benefit from advances in precision medicine.
